PCI Pharma Services has completed the previously announced acquisition of Lyophilization Services of New England, Inc. (LSNE), a contract development and manufacturing organization (CDMO) headquartered in Bedford, New Hampshire.
 
LSNE serves global pharmaceutical, biotechnology and medical device companies, offering cGMP aseptic fill-finish capabilities and expertise in and ability to scale lyophilization, an important manufacturing process commonly used with injectable and biologic therapies. The acquisition adds five FDA-approved facilities in the U.S. (New Hampshire, Wisconsin) and Europe (Spain), with a sixth expecting approval over the coming months, and three additional facilities under development, to strengthen PCI’s global 30-site network.
 
PCI is now a fully integrated CDMO, offering specialty manufacturing capabilities for injectables including biologics like vaccines, MABs, proteins, oligonucleotides, in addition to its pharma clinical and commercial packaging services. The injectable CDMO market is a high-growth segment, with more than 8,000+ small molecule candidates in the pipeline, outpacing the overall pharmaceutical outsourcing market. PCI is making significant investments, like this acquisition, to respond to the evolving industry landscape.